Call or text (855) 420-1626 | Need support? Click here.
To opt-out of texting, simply reply STOP at anytime.
Call or text (855) 420-1626
To opt-out of texting, simply reply STOP at anytime.
In the ever-evolving landscape of medical treatments and pharmaceutical advancements, staying informed is not just a necessity—it's a responsibility. As a trusted partner, Infinity Medical Marketing is here to shed light on recent developments involving Eli Lilly that might impact your practice, especially for those providing weight loss solutions with injectables like semaglutide and terzepatide.
Eli Lilly has recently initiated
legal action against compound pharmacies and wellness centers for allegedly selling knockoff versions of their weight loss drug, Mounjaro. This move raises concerns for many of our clients who rely on these pharmacies to make treatments more affordable for their patients. While brand-name drugs might be outside the financial reach for some patients, compounded alternatives have been a viable solution.
In a significant announcement, Eli Lilly has announced their plans to offer telehealth services directly to patients seeking weight loss programs. This could potentially redirect patients away from their regular healthcare providers.
Advice for Clinics:
Remember, it's not a time for panic, but for strategic planning and adaptation. Infinity Medical Marketing is here to assist with:
In light of these developments, adapting and staying ahead of the curve is essential. Infinity Medical Marketing is committed to helping you navigate these changes, ensuring your practice thrives in this dynamic environment.
Stay informed, stay prepared, and remember,
we're in this together.
- Infinity Medical Marketing
Email: hello@infinitymedicalmarketing.com
Phone: 855-420-1626
© Copyright 2024 | All Rights Reserved | Infinity Medical Marketing | Privacy Policy | Terms of Use | Texting Terms of Use | Accessibility